SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer

SLXN

Related stories